Dry Age-Related Macular Degeneration

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, discusses targeting mitochondria in retinal disease treatment.

WAILEA, Hawaii — In this Healio video perspective from Retina 2024, Marion R. Munk, MD, PhD, overviews data investigating multiwavelength photobiomodulation for the treatment of dry age-related macular degeneration.

LumiThera submitted a de novo request to the FDA to reclassify the Valeda light delivery system as a Class II device for the treatment of dry age-related macular degeneration, according to a press release.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Baruch D. Kuppermann, MD, PhD, speaks about some products in development that share a common theme.

ROME — Two injectable drugs with mitochondrial-stabilizing properties, risuteganib and elamipretide, show promise in reversing vision loss in dry age-related macular degeneration.

The first-in-human trial assessing the safety and efficacy of the PRIMA photovoltaic retinal stimulation microchip for severe central vision impairment due to dry age-related macular degeneration showed positive outcomes at 4 years.

RetinalGeniX Technologies announced that it submitted patent applications for investigational drug candidates RTG-2023 and RTG-2024, for age-related macular degeneration and Alzheimer’s, respectively.

SAN FRANCISCO — It is important for ophthalmologists to understand FDA indications and develop a proper practice implementation strategy for new retinal drugs entering the market, according to a speaker here.

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Tarek S. Hassan, MD, discusses a novel treatment paradigm under investigation for geographic atrophy and dry age-related macular degeneration.

SEATTLE — In this Healio Video Perspective from the ASRS meeting, David A. Eichenbaum, MD, FASRS, overviews the efficacy of aHtrA1 Fab for the treatment of geographic atrophy secondary to dry age-related macular degeneration.